Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine

Published on 04 Jun 2024
Last Updated on 04 Jun 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if:

  • in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline;

  • in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline.

Funding status

Galcanezumab 120 mg/mL solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

MAF assistance does not apply to galcanezumab 100 mg/mL solution for injection in pre-filled syringe, or any formulations or strengths of eptinezumab, erenumab or fremanezumab.

Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine (Published 4 Jun 24) [PDF, 131 KB]

PES Monoclonal antibodies for preventing migraine (Published 4 Jun 24) [PDF, 62 KB]